TTUHSC Research Progress Update
I wanted to get a note out before the end of the year holidays were upon us.
There are at least three reasons that we do research:
(1) We learn about how to improve our lives and those of our
pet and agricultural animals.
(2) Research dollars recycle in the local community.
(3) Research is the basis of innovation and entrepreneurship.
You may be able to think of other reasons, but those three things are represented
more and more in what we do at TTUHSC. Immediately below is our research growth expressed
in dollars. That is one metric, but not the only one. We also measure research growth
in terms of the good we do. We are starting to see that in patent presence and our
growth in reputation.
Our research growth continues to be robust, with 26% and 21% growth in support in
the last two years.
In terms of moving our reputation forward, we achieved full AAHRPP accreditation this
year, something that we share with only a dozen other excellent Institutions in the
State such as Baylor College of Medicine, UT (Austin, Galveston, Houston, San Antonio),
DeBakey VA Medical Center and Texas A&M.
AAHRPP accreditation indicates that we follow rigorous standards for ethics, quality,
and protections for human research. We have earned a place among the world's most
respected, trustworthy research organizations.
In terms of “doing good,” patents are one metric that we can use to evaluate our progress.
Until this month, TTUHSC had earned only a single patent in the last 5 years. During
October, 2015, we earned three, two of which are licensed.
(1) Dr. Siddiqui’s patented Schisto Vaccine is a good example. Its impact to world
health could be huge.
(2) Drs. Sam Prien and Lindsey Penrose patented a sex selection method that can be
used with artificial insemination in humans and animals. That technology has been
licensed to Reproductive Solutions Inc., a Lubbock start-up company run by John Smothers.
This is an example of creating economic growth.
(3) Drs. Chiriva-Internati, Cobos, and an inventor from UC-San Francisco. It is licensed
to Kiromic (Lubbock). The research was funded by a Phase I SBIR grant. Galectin-3C
Combination Therapy for Human Cancer.
If you want to learn more about the patent and intellectual property process in the
TTU System, contact Dr. David Snow email@example.com.
We expect to have a mini-symposium on drug development at TTUHSC as a way of building
synergy. http://www.ttuhsc.edu/research/files/Drug_Development_Symposium_schedule_final.pdf. Please join us—students and postdocs are welcome. No registration is needed, but
you need to sign up for lunch—see the URL above. If you have ideas for the topic of
future mini-symposia, please send me a note.
The Presidential Lectures are set for the next three years: http://www.ttuhsc.edu/research/misc/presidential_lectures.aspx (to accommodate the 2015 speaker the 2015 presentation had to be delayed until early
As many of you know, we are engaged in a search for a new attending veterinarian and
hope to have someone in place by the spring. We have some very good candidates. Read
the details here: http://www.ttuhsc.edu/research/misc/vet_update.aspx
It has been a great pleasure for me to see the faculty growth in research and all
your enthusiasm in 2014 and 2015. 2016 will be even better.
All good holidays and best wishes for the coming year.
Fall 2015 Progress Letter
Spring 2015 Progress Letter
Winter 2015 Progress Letter
Fall 2014 Progress Letter
Summer 2014 Progress Letter